
Although targeted treatments for neuroproliferative dyspareunia remain a future goal, clinicians can use current findings to counsel patients that differential nerve growth around endometriosis lesions may underlie their experience of deep dyspareunia—with serum NGF biomarkers and upstream mechanistic research identified as key next steps.

